Back to top
more

BioSpecifics Technologies Corp (BSTC)

(Delayed Data from NSDQ)

$66.72 USD

66.72
62,398

+0.21 (0.32%)

Updated May 3, 2019 04:00 PM ET

After-Market: $66.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Lannett (LCI) Could Be Positioned for a Slump

Lannett (LCI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

    Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap

    Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.

      Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher

      Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

        Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status

        Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.

          Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

          Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

            Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

            Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

              Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

              Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies

                5 Stocks With Recent Price Strength to Strengthen Portfolio

                Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

                  United Therapeutics In-Licenses Rights to IPF Candidate

                  United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.

                    Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher

                    Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

                      Ironwood Stock Up, Heart Candidate Gets Fast Track Status

                      The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.

                        KemPharm Posts Positive Top-Line Results on KP415 Prodrug

                        KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

                          Tilray (TLRY) Looks Good: Stock Adds 8.5% in Session

                          Tilray (TLRY) was a big mover last session, as the company saw its shares rise more than 8% on the day amid huge volumes.

                            The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor

                            The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor

                              Sweta Killa headshot

                              5 Top-Ranked Nasdaq Stocks Defying the Worst September Start

                              There are still winners on the index across industries that are easily surviving the worst start to September and have a solid Zacks Rank #1 (Strong Buy) or 2 (Buy).

                                Spectrum Pharmaceuticals (SPPI) Catches Eye: Stock Jumps 5.7%

                                Spectrum Pharmaceuticals (SPPI) shares rose nearly 6% in the last trading session, amid huge volumes.

                                  Tesaro (TSRO) Surges: Stock Moves 5.5% Higher

                                  Tesaro (TSRO) shares rose nearly 6% in the last trading session, amid huge volumes.

                                    What Makes Taro Pharmaceutical (TARO) a Strong Sell?

                                    Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

                                      Biogen Begins Phase III Study on Ischemic Stroke Candidate

                                      Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.

                                        Zacks.com highlights: Verso, Johnson Outdoors, BioSpecifics Technologies and Luxfer Holdings

                                        Zacks.com highlights: Verso, Johnson Outdoors, BioSpecifics Technologies and Luxfer Holdings

                                          BioCryst Pharmaceuticals (BCRX) Looks Good: Stock Adds 6% in Session

                                          BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

                                            4 Stocks With Recent Price Strength to Maximize Your Gains

                                            Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

                                              Affimed (AFMD) Soars: Stock Adds 10.8% in Session

                                              Affimed (AFMD) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.

                                                Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol

                                                Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.

                                                  Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1%

                                                  Portola Pharmaceuticals (PTLA) shares rose more than 9% in the last trading session, amid huge volumes.